View all news

Masimo Announces $1 Million Performance Guarantee

10/02/2008
Launches 'Fact vs. Fiction' website.

IRVINE, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Masimo Corporation (Nasdaq: MASI), the inventor of Pulse CO-Oximetry and Measure-Through-Motion-and-Low-Perfusion pulse oximetry, today announced a $1 million performance guarantee and unveiled a new website aimed at separating fact from fiction. The 'Fact vs. Fiction' website, http://www.nellcorfiction.com, will openly address and dissect erroneous and misleading information circulated by Nellcor, a division of Covidien.

The superior performance and clinical benefits of Masimo SET pulse oximetry technology are proven everyday at thousands of hospitals, and reinforced by more than 100 independent and objective studies demonstrating that Masimo provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.

Masimo is so confident in its ability to provide clinicians with the best performing pulse oximetry technology, the company is backing up its technology with a $1 million performance guarantee for hospitals planning to upgrade their pulse oximetry technology hospital-wide. If Masimo SET does not outperform Nellcor in an objective side-by-side clinical evaluation, Masimo will pay the hospital up to $1 million to acquire Nellcor's pulse oximetry. Additional performance guarantee details can be found online at http://www.masimo.com.

Joe E. Kiani, Founder and CEO of Masimo, stated; "The Fact vs. Fiction website was developed in response to reports about Nellcor's constant and aggressive dissemination of false information to clinicians. The website exposes Nellcor fictions and delivers facts backed by proof. Our dedication and commitment to 'improving patient outcomes and reducing cost of care by taking noninvasive monitoring to new sites and applications' means that we not only owe it to care providers to innovate breakthroughs in noninvasive monitoring, but we must also do our part to educate, and sometimes even expose obfuscations and falsehoods."

About Masimo

Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.

Forward Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo SET is superior to all other commercially-available pulse oximetry technologies, and risks related to our assumption that truths asserted in the 'Fact vs. Fiction' website (http://www.nellcorfiction.com) will serve to substantially increase awareness of Nellcor fictions and/or Masimo's superiority, as well as other factors discussed in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the fiscal quarter ended June 28, 2008, filed with the Securities and Exchange Commission ("SEC") on August 5, 2008, which may be obtained for free at the SEC's website at http://www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our Quarterly Report on Form 10-Q for the fiscal quarter ended June 28, 2008, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.

SOURCE Masimo Corporation

Multimedia Files:

Categories: Press Releases
View all news